skip to main content
UK Health Security Agency

H357

H357

Catalogue No.

06092004

Cell Line Name

H357

Cell Line Description

Established from a squamous cell carcinoma (SCC) of the tongue (20mm) of a 74 year-old male patient. STNMP stage I, well differentiated, node negative tumour. Mutant p53, codon 110 exon 4, G to A; the previously reported mutant Ha-ras status of this cell line: codon: 13, G to A, codon 61, A-G is under investigation. This cell line is highly responsive to TGF beta and undergoes epithelial to mesenchymal transition. It expresses high levels of TGF beta1. Fahey et al (1996). Tumourigenic in athymic nude mice on subcutaneous injection and non-tumorigenic on orthotopic injection. Haplotype information: A*02,A*31; B*40,B*44; Cw*03,Cw*05

General Info

Species

Human

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Receptors

TGFbeta type I receptor, TGFbeta II receptor, TGFbeta III receptor

Tissue of Origin

Tongue

Morphology

Polygonal

Karyotype

Not specified

Disease

Squamous Cell Carcinoma

Culture Conditions

Cell Type

Endothelial-like

Subculture Routine

Split sub-confluent cultures (70-80%), approximately every 5-6 days, 1:8 to 1:10 using 0.05% trypsin/EDTA; 5% CO₂; 37°C. Suggested seeding density 5 x 1000 cells/cm². Cells can take approximately 10 minutes to detach, an alternative is to trypsinise 2 to 3 times with fresh trypsin for shorter periods for each trypsin application. Avoid knocking flasks during the trypsinisation process as this can lead to loss of viability.

Culture Medium

DMEM:HAMS F12 (1:1) + 2mM Glutamine + 10% Foetal Bovine Serum (FBS) + 0.5 ug/ml sodium hydrocortisone succinate

Growth Mode

Adherent

Additional Info

Depositor

Professor Stephen Prime, Department of Oral & Dental Science, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol BS1 2LY

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Prime et al., 1994; Int J Cancer 56, 406-412, Prime et al., 1990; J Pathol 160, 259-269, Prime et al., 1994 Br J Cancer 69, 8-15; Yeudall et al., 1993; Eur J Cancer B Oral Oncol 29B, 63-67 & 1995 31B 136-143. Fahey et al., 1996 PMID:8855977

Bibliography

Fahey et al., (1996) Dysregulation of autocrine TGF-beta isoform production and ligand responses in human tumour-derived and Ha-ras-transfected keratinocytes and fibroblasts. Br J Cancer. Oct;74(7):1074-80 PMID:8855977. Davies et al., 2005; J Cell Biochem 95, 918-931.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: H357 (ECACC 06092004).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.